Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan
| Errataetall: |
CommentOn: J Hepatol. 2022 Apr;76(4):812-821. - PMID 34871626 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Journal of hepatology - 77(2022), 2 vom: 10. Aug., Seite 569-571 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nakatsuka, Takuma [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.07.2022 Date Revised 04.10.2022 published: Print-Electronic CommentOn: J Hepatol. 2022 Apr;76(4):812-821. - PMID 34871626 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jhep.2022.03.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338189211 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338189211 | ||
| 003 | DE-627 | ||
| 005 | 20231226000119.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2022.03.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338189211 | ||
| 035 | |a (NLM)35288188 | ||
| 035 | |a (PII)S0168-8278(22)00138-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nakatsuka, Takuma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.07.2022 | ||
| 500 | |a Date Revised 04.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Hepatol. 2022 Apr;76(4):812-821. - PMID 34871626 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Hepatitis C virus | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Liver stiffness measurement (LSM) | |
| 650 | 4 | |a Sustained virological response (SVR) | |
| 650 | 4 | |a compensated advanced chronic liver disease (cACLD) | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Tateishi, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakagomi, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Minami, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Koike, Kazuhiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hepatology |d 1993 |g 77(2022), 2 vom: 10. Aug., Seite 569-571 |w (DE-627)NLM012604372 |x 1600-0641 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2022 |g number:2 |g day:10 |g month:08 |g pages:569-571 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhep.2022.03.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2022 |e 2 |b 10 |c 08 |h 569-571 | ||